<DOC>
	<DOCNO>NCT01247090</DOCNO>
	<brief_summary>The death rate patient endstage renal disease ( ESRD ) dialysis year 20 % , diseases related heart blood vessel cause half . About 60 % patient hemodialysis high blood pressure , poorly control . Normal blood pressure patient greatly improve chance living . Increased fluid body bloodstream major cause hypertension patient ESRD . Fluid removal hemodialysis often limit symptom low blood pressure procedure . Therefore increase fluid related high blood pressure ongoing many patient . Arginine vasopressin ( AVP ) hormone naturally produce body little effect blood pressure healthy people , act powerful vasoconstrictor ( narrows blood vessel ) blood pressure threaten . Recent study show little AVP , patient likely low blood pressure dialysis limit fluid removal , effect reverse give patient low dos AVP . This phase II trial find two dos AVP ( .15 .30 mU kg-1 min-1 ) , combination standard therapy , work best change interdialytic 44-hour ambulatory systolic blood pressure 2 week . Patients enroll study divide three group . One group give 0.15 mU kg-1 min-1 dose AVP dialysis session 2-week period ; second group give AVP 0.3 mU kg-1 min-1 interval ; third group give normal saline ( placebo ) interval . All patient closely monitor side-effects .</brief_summary>
	<brief_title>Study Effect Intradialytic Vasopressin Chronic Hypertension Patients With End Stage Renal Disease</brief_title>
	<detailed_description>This pilot study originally enrol group 12 subject ( 4 subject per arm ) order demonstrate feasibility primary outcome measure , interdialytic 44-hour ambulatory systolic blood pressure . Data original subject complete result post . We reopen study enrollment increase total number subject 36 ( 12 subject per arm ) order make initial statistical comparison group , help establish great confidence novel method control blood pressure dialysis patient .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Arginine Vasopressin</mesh_term>
	<mesh_term>Vasopressins</mesh_term>
	<criteria>End Stage Renal Disease Hemodialysis great 3 month Hypertension ( Predialysis systolic blood pressure ( SBP ) great 140 mmHg , average precede 6 dialysis treatment ) Stable dry weight precede 6 dialysis treatment Age le 18 year Clinically significant vascular disease* Predialysis systolic blood pressure ( SBP ) great 200 mmHg diastolic blood pressure ( BP ) &gt; 110 Pregnancy Long QTc syndrome ( electrocardiogram ( ECG ) perform unavailable within last 3 month ) Clinically significant vascular disease define follow occur precede three month : angina , claudication , transient ischemic attack , myocardial infarction , cerebrovascular accident , decompensated heart failure . Furthermore , patient exclude history ischemic colitis Raynaud 's disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>hypertension</keyword>
	<keyword>end stage renal disease</keyword>
	<keyword>vasopressin</keyword>
	<keyword>Arginine Vasopressin</keyword>
	<keyword>AVP</keyword>
	<keyword>PitressinÂ®</keyword>
</DOC>